Previous 10 | Next 10 |
Theravance Biopharma (NASDAQ:TBPH): Q3 GAAP EPS of -$0.48 beats by $0.08. Revenue of $13.2M (-27.7% Y/Y) misses by $1.49M. Press Release For further details see: Theravance Biopharma EPS beats by $0.08, misses on revenue
Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Implied 35% share of YUPELRI® (revefenacin) US net sales[1]: $13.8 million, up 7% from Q3 2020 - TRELEGY Q3 2021 global net sales: $449 million, up 77% from Q3 2020[2]...
Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021 PR Newswire DUBLIN , Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), will report its third quarter 2021 financial results and provide a business update a...
After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward. Arena Pha...
Higher commodity prices presented a key theme in Wednesday's equity market. Oil producers rallied on the back of strong crude prices, with notable gains coming from EOG Resources (NYSE:EOG), Diamondback Energy (NASDAQ:FANG), Occidental Petroleum (NYSE:OXY) and Marathon Oil (NYSE:MRO). Meanwhi...
Shares of Theravance Bipharma (NASDAQ: TBPH) really took it on the chin Wednesday. Investors sold off the stock following another clinical-trial flop by the company, and its subsequent announcement of severe belt-tightening. This morning, Theravance divulged the top-line results...
Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals ATNM +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. Seres Therapeutics (...
Gainers: Ampio Pharmaceuticals (NYSE:AMPE) +22%, 180 Life Sciences (NASDAQ:ATNF) +17%, Brainstorm Cell Therapeutics (NASDAQ:BCLI) +15%, Instil Bio (NASDAQ:TIL) +16%, G Medical Innovations (NASDAQ:GMVD) +15%. Losers: Nuwellis (NASDAQ:NUWE) -26%...
Nuwellis (NASDAQ:NUWE) -28% after proposes stock offering Theravance Biopharma (NASDAQ:TBPH) -20% after ampreloxetine misses primary endpoint in late-stage orthostatic; on headcount cut to focus on respiratory disease portfolio hypotension study DAVIDsTEA (NASDAQ:DTEA...
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio - Implements significant cost reduction program - Expects to be sustainably cash flow positive beginning 2H 2022 - Investor conference call and webcast today at 8:00 AM ET (5...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...